Key result
Faricimab, a bispecific antibody targeting Ang-2 and VEGF-A, displays improved and sustained efficacy for treating diabetic macular edema and neovascular age-related macular degeneration.
Why the study?
Does faricimab improve vision outcomes and reduce treatment burden in patients with retinal vascular diseases?
Design
Literature review
Authors
Loading...
Faricimab via Ang-2/Tie-2 inhibition may improve retinal vascular disease management; extends late-phase trial data for dual-pathway targeting.
Does faricimab improve vision outcomes and reduce treatment burden in patients with retinal vascular diseases?
Faricimab, a novel bispecific antibody targeting Ang-2 and VEGF-A, shows promising efficacy and durability for treating retinal vascular diseases.
Khan et al. (2020) conducted a review in Retinal vascular diseases. Faricimab was evaluated. Faricimab, a bispecific antibody targeting Ang-2 and VEGF-A, displays improved and sustained efficacy for treating diabetic macular edema and neovascular age-related macular degeneration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: